Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study

Alexandra Savinkina,1,2 Alyssa Bilinski,3 Meagan Fitzpatrick,4 A David Paltiel,2,5 Zain Rizvi,6 Joshua Salomon,7 Thomas Thornhill,1,2 Gregg Gonsalves6,8

ABSTRACT

Objectives While almost 60% of the world has received at least one dose of COVID-19 vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population of low-income countries (LICs) has received a full primary vaccine series, compared with over 70% of the population of high-income nations.

Design We used economic and epidemiological models, parameterised with public data on global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up vaccination programmes in LICs and lower-middle-income countries (LMICs) in 2022 in the context of global spread of the Omicron variant of SARS-CoV2.

Setting Low-income and lower-middle-income nations.

Main outcome measures Outcomes were expressed as number of avertable deaths through vaccination, costs of scale-up and cost per death averted. We conducted sensitivity analyses over a wide range of parameter estimates to account for uncertainty around key inputs.

Findings Globally, universal vaccination in LIC/LMIC with three doses of an mRNA vaccine would result in an estimated 1.5 million COVID-19 deaths averted with a total estimated cost of US$61 billion and an estimated cost per COVID-19 death averted of US$40 800 (sensitivity analysis range: US$7400–US$81 500). Lower estimated infection fatality rates, higher cost-per-dose and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in the analysis.

Conclusions Scaling up COVID-19 global vaccination would avert millions of COVID-19 deaths and represents a reasonable investment in the context of the value of a statistical life. Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this effort should be an urgent priority.

INTRODUCTION

As of 7 January 2022, 59% of the global population had received at least one dose of a COVID-19 vaccine, 50% had received a full primary vaccine course and 7% had received an additional booster. In low-income countries (LICs),1 only 9% of people had received any dose of vaccine, and only 4% had received two doses.2 The barriers to global access to COVID-19 vaccines have been well described. Many have emphasised the need to scale up mRNA vaccine production to remedy these, including the transfer of technology for vaccine production to regional hubs to scale up supply more quickly as recommend by the WHO.34 Beyond humanitarian implications, lingering inequities in access to COVID-19 vaccines will delay the worldwide recovery from the pandemic and continue to fuel the rise of new variants as the virus spreads in many parts of the globe.3

Because the most dire complications of COVID-19 occur in older people and the age structure in many lower-middle-income
countries (LMICs) skews relatively young, it was initially assumed that the mortality burden in LICs and LMICs from COVID-19 would be less severe. However, deaths in LIC/LMIC have been growing as the pandemic has continued, likely due in part to underlying comorbidities. LICs/LMICs now account for over 50% of the global mortality burden with some researchers suggesting they bear 80% of global COVID-19 mortality when accounting for underreporting of deaths in these regions. Indeed, due to under-reporting, the recorded number of infections and deaths are likely gross underestimates of the true burden of the pandemic in LICs/LMICs. Model-based excess mortality estimates suggest that COVID-19-related mortality might be as high as 35 times higher than reported figures in these settings.

The emergence of the Omicron variant has led to steep increases in infections and hospitalisations worldwide, causing significant health losses and disruptions to daily life, commerce and travel, as well as severe stress on the healthcare sector dealing with a high volume of patients in many places across the globe. While Omicron appears to be less severe than other variants, it is also more transmissible and more able to escape both existing immunity garnered by previous infections and that conferred through vaccination.

Previous literature has discussed the feasibility and costs of global vaccination for COVID-19, placing the total cost somewhere between US$25 billion and US$50 billion. However, the dangers of not vaccinating come at a potential worldwide cost of trillions of dollars. WHO estimates the total cost of vaccine manufacturing and delivery, we evaluated vaccines. In addition, using estimates of the total cost of vaccination body to estimate a 'number of avertable deaths' for future death from COVID-19, assuming those who are previously vaccinated and those who have previous immunity are protected at least in part. Third, we predicted the number of deaths that could be prevented based on estimated vaccine effectiveness.

We evaluated two potential dosage scenarios, one which estimates cost and effect of global vaccination with two doses of mRNA vaccine (‘two-dose scenario’), and one with three doses of mRNA vaccine, the primary full course plus an additional booster (‘three-dose scenario’). The two-dose scenario assumes that everyone who is unvaccinated at the start of the simulation will receive two doses, and those with one vaccine dose will receive an additional dose. The three-dose scenario calculation assumes those who are unvaccinated will receive three doses, those with two doses will receive one additional dose and those with one dose will receive two additional doses. For cost calculations, we multiplied the number of doses needed for full population vaccination under these dosage scenarios by the cost per dose.

We estimated the number previously infected with COVID-19 in each region using estimates of regional COVID-19-related mortality and IFR:

\[ I_i = \left( \frac{M_i}{IFR_{pO}} \right) / P_i \]  

(1)

\( I_i \) is the proportion of the population in region \( i \) with previous COVID-19 infection, \( M_i \) is the number of deaths attributed to COVID-19 since March 2020, \( IFR_{pO} \) is the IFR of COVID-19 pre-Omicron, and \( P_i \) is the population of region \( i \).

As mortality due to COVID-19 is not well measured in most LIC/LMIC, we estimate \( M_i \) in two ways. One method uses reported COVID-19 deaths as the COVID-19 mortality estimate, with the understanding that this would likely underestimate mortality due to COVID-19. Alternatively, we use excess deaths estimates as the indicator of COVID-19 mortality. The modelled estimates of excess death have wide CIs, and

METHODS

Analytical approach

We developed a probability-tree model to assess potential deaths averted, total vaccination costs and cost per death averted assuming vaccination scale up to 100% coverage in LIC/LMIC. We assumed the main COVID-19 variant to be Omicron, which leads to less severe disease than the prior Delta variant but has greater transmissibility and immune escape. We assumed that all persons previously unvaccinated and uninfected and some individuals with previous immune protection would be infected with SARS-CoV-2 within the year, which was the time frame of our model. We further assumed that some percentage of those infected would die based on infection fatality ratios (IFRs) estimated for the Omicron variant for spike naïve, previously infected and vaccinated individuals. No discounting of outcomes was used given the short (1 year) time frame of the analysis. As the only cost included in analysis was the cost of vaccination, the perspective is that of the vaccinating body, whether that be within-country or international.

Our analysis of avertable deaths proceeded in three steps. First, we used mortality data (both estimates of excess mortality and reported COVID-19 deaths) over the last 22 months to estimate cumulative infections of COVID-19 across LIC/LMIC in all regions. Second, we used the number of previously infected people per country, the number of already vaccinated people per country and the IFR to estimate a ‘number of avertable deaths’ for future death from COVID-19, assuming those who are previously vaccinated and those who have previous immunity are protected at least in part. Third, we predicted the number of deaths that could be prevented based on estimated vaccine effectiveness.
therefore, we use both the median estimate and the 95% confidence limits in our analyses to reflect this uncertainty.

We estimated the number of potentially avertible deaths \((D_{i,d})\) from COVID-19 based on prior immunity and prior vaccination in each region with the two-dose and three-dose scenario:

For two-dose scenario:

\[
D_{i,2} = P_i \times IFR_{Omicron} \times \left[ I_i \times (1 - V_i) \times (1 - N) \times (1 - I_i) \times (1 - V_i) \right] 
\]

(2a)

For three-dose scenario:

\[
D_{i,3} = P_i \times IFR_{Omicron} \times \left[ I_i \times (1 - V_i) \times (1 - N) \times (1 - I_i) \times V_i \times (1 - E_2) \right] 
\]

(2b)

\(I_i\) is calculated in equation 1, \(IFR_{Omicron}\) is the IFR of the Omicron variant of COVID-19, \(V_i\) is the proportion of the population in region \(i\) previously vaccinated with two doses of mRNA vaccine, \(N\) is the protection against mortality conferred by natural immunity and \(E_2\) is the vaccine effectiveness against mortality for two doses of mRNA vaccine.

We then estimated the number of deaths averted \((A_{i,d})\):

For two-dose scenario:

\[
A_{i,2} = D_{i,2} \times E_2 
\]

(3a)

For three-dose scenario:

\[
A_{i,3} = D_{i,3} \times E_3 
\]

(3b)

Where \(E_3\) is the vaccine effectiveness against mortality from three doses of vaccine.

We estimate the total number of vaccine doses necessary to fully vaccinate a region \((X_{i,d})\):

For two-dose scenario:

\[
X_{i,2} = P_i \times \left( Y_i + 2 \times (1 - Y_i - V_i) \right) 
\]

(4a)

For three-dose scenario:

\[
X_{i,3} = P_i \times \left( V_i + 2 \times Y_i + 3 \times (1 - Y_i - V_i) \right) 
\]

(4b)

\(Y_i\) is the proportion of the population of region \(i\) vaccinated with only one dose of vaccine.

We estimated total cost of vaccination for each region \((T_{i,d})\):

For two-dose scenario:

\[
T_{i,2} = X_{i,2} \times C 
\]

(5a)

For three-dose scenario:

\[
T_{i,3} = X_{i,3} \times C 
\]

(5b)

\(X_i\) comes from equations 4a and 4b and \(C\) was the cost per vaccine dose.

Finally, we estimated cost per death averted \((Z_{i,d})\):

For two-dose scenario:

\[
Z_{i,2} = \frac{T_{i,2}}{A_{i,2}} 
\]

(6a)

For three-dose scenario:

\[
Z_{i,3} = \frac{T_{i,3}}{A_{i,3}} 
\]

(6b)

\(T_{i,d}\) comes from equations 5a,b, and \(A_{i,d}\) comes from equations 3a,b.
Table 2  Model parameter estimates and ranges

| Parameter                                                                 | Base-case parameters | Sensitivity analysis | Source          |
|---------------------------------------------------------------------------|----------------------|----------------------|-----------------|
| Infection fatality ratio (IFR) for pre-Omicron COVID-19                    | 5/1000               |                      |                 |
| IFR for Omicron variant of COVID-19                                       | 1/1000               | 5/10 000             |                 |
| Natural immunity protection against COVID-19 mortality                    | 80%                  |                      |                 |
| Vaccine effectiveness against COVID-19 mortality, two dose                | 80%                  | 90%                  |                 |
| Vaccine effectiveness against COVID-19 mortality, two dose+booster        | 90%                  | 99%                  |                 |
| Cost per vaccine dose administered                                        | US$7                 | US$5–US$10           |                 |

Parameter values

Data on population by region and number of vaccinations came from Our World in Data and WHO (table 1). Data on reported COVID-19 mortality and excess mortality by region for 2020 and 2021 came from the Institute for Health Metrics and Evaluation and from The Economist.

Countries were assigned to regions based on World Bank designations. Only LICs and LMICs were included in the main analysis. Population characteristics for each are shown in table 1.

We extracted estimates of the IFR (for pre-Omicron and Omicron), natural immunity protection against mortality following past COVID-19 infection, vaccine effectiveness against mortality, and cost per dose of vaccine administered from the published literature (table 2).

For the base-case analysis, we chose realistic parameter values with regards to the cost and benefits of scaling global COVID-19 vaccination. We set the COVID-19 Omicron variant IFR as one fifth of the pre-Omicron estimate (1 in 1000 vs 5 in 1000), natural immunity protection against mortality as 80%, and vaccine effectiveness against mortality as 80% for the two-dose scenario and 90% for the three-dose scenario (table 1). Production and delivery of an mRNA vaccine dose was estimated to cost US$7, the halfway point between relevant estimates of US$5–US$10.

Sensitivity analysis

Given the uncertainty surrounding several model parameters, we sought to assess the robustness of our conclusions under a wider range of assumptions about the values of our parameters alone and in combination. We therefore conducted a sensitivity analysis assessing the number of deaths averted and the cost-per-death averted while varying IFR, vaccine effectiveness and vaccine cost. We ranged IFR from a ‘high’ estimate of 5/1000 consistent with pre-Omicron levels, to a ‘low’ estimate of 5/10 000, consistent with mortality reduction observed for Omicron in the USA. We ranged vaccine effectiveness against mortality for the two-dose scenario from 80% to 95%, and for the three-dose scenario from 90% to 99%, given the uncertainty of vaccine effectiveness against Omicron as well as potential future variants. Vaccine cost was ranged from US$5 to US$10 per dose (table 1).

As a scenario analysis, we examined the value of vaccines under imperfect uptake. For this analysis, avertible deaths were reduced from 100% to 75%, consistent with vaccine uptake observed in the USA. Cost for vaccine production was kept at 100%, with the assumption that enough vaccine is produced for full vaccination but uptake is reduced.

We also assessed the potential benefit of vaccination in a scenario of high prior infection with COVID-19, since Omicron may spread through the world faster than vaccination can take place. This sensitivity analysis assumed that 100% of the population in LIC/LMIC would be previously infected by COVID-19 prior to vaccination, such that mortality risk is entirely among those with partial natural protection.

Patient and the public involvement

No patient involved.

RESULTS

Base-case analysis

For the two-dose scenario with base case parameter estimates (table 2), using excess mortality to estimate prior infections and number at risk, scaling up vaccination to provide two doses of mRNA vaccine to everyone in LIC/LMIC would cost US$35.5 billion and avert 1.3 million deaths from COVID-19, at a cost of US$26900 per death averted (table 3). Scaling up vaccination to provide three doses of mRNA vaccine to everyone in LIC/LMIC would cost US$61.2 billion and avert 1.5 million deaths from COVID-19 at a cost of US$40 800 per death averted (table 3).

Sensitivity analysis

We considered a wide range of values for IFR and vaccine effectiveness (table 2). For the two-dose scenario, the cost-per-death averted ranged from US$4500 when IFR was 5/1000 and vaccine effectiveness against mortality was 95%, to US$53 800 when IFR was 5/10 000 and vaccine effectiveness against mortality was 80% (figure 1). Deaths

Savinkina A, et al. BMJ Open 2022;12:e061752. doi:10.1136/bmjopen-2022-061752

Open access
averted with the same parameter estimates ranged from 7.8 million to 0.7 million, respectively (figure 2).

Considering an IFR of 1/1000 and a vaccine effectiveness of 80% with the two-dose scenario, varying the cost-per-dose from US$5 to US$10 led to a range of cost-per-death estimates of US$19,200 with a US$5 cost-per-dose to US$38,400 with a US$10 cost-per-dose (figure 1).

Examining the implication of this parameter uncertainty for the three-dose scenario, the cost-per-death averted ranged from US$7,400 when IFR was 5/1000 and vaccine effectiveness against mortality was 99% to US$81,500 when IFR was 5/1000 and vaccine effectiveness against mortality was 90% (figure 1). Deaths averted with the same parameter estimates ranged from 8.3 million to 0.8 million, respectively (figure 2).

Table 3  Model results for total cost of global vaccination of low and lower-middle income countries (in billions US$), total deaths averted (in millions) and cost per death averted (US$)

| Total cost (US$, billion) | Two dose scenario | Three dose scenario |
|---------------------------|-------------------|--------------------|
| Total deaths averted (million) | US$35.52 | US$61.21 |
| Using reported COVID-19 deaths to calculate prior infection | 2.14 | 2.40 |
| Using excess mortality estimates to calculate prior infection (and 95% CI)* | 1.32 (0.87 to 1.97) | 1.50 (1.02 to 2.22) |
| Cost per death averted (US$) | | |
| Using reported COVID-19 deaths to calculate prior infection | US$16,700 | US$25,500 |
| Using excess mortality estimates to calculate prior infection (and 95% CI)* | US$26,900 ($18,000 to US$40,000) | US$40,800 ($27,600 to US$59,900) |

The model assumes an IFR for pre-Omicron COVID-19: 5/1000, IFR for Omicron: 1/1000, cost per dose US$7, natural immunity protection against mortality 80%, vaccine effectiveness against mortality with two doses: 80%, vaccine effectiveness against mortality with three doses: 90%

*95% CI from excess mortality calculations from The Economist

Considering an IFR of 1/1000 and a vaccine effectiveness of 80% with the three-dose scenario, varying the cost-per-dose from US$5 to US$10 led to a range of cost-per-death estimates of US$29,100 with a US$5 cost-per-dose to US$38,200 with a US$10 cost-per-dose (figure 1).

Vaccine hesitancy analysis

For the two-dose scenario with base-case parameter estimates, using excess mortality to estimate prior infections and number at risk, reducing vaccine uptake to 75% but keeping cost at 100% would avert 1.0 million deaths at a cost of US$25,900 per death averted. When considering a wide range of values for IFR and vaccine effectiveness, cost-per-death averted ranged from US$7,200 when IFR was 5/1000 to US$71,700 when IFR was 5/1000. Deaths averted with the same parameter estimates ranged from 5.0 million to 0.5 million, respectively.
For the three-dose scenario with base case parameter estimates, using excess mortality to estimate prior infections and number at risk, reducing vaccine uptake to 75% but keeping cost at 100% would avert 1.2 million deaths at a cost of US$63,400 per death averted. When considering a wide range of values for IFR and vaccine effectiveness, cost-per-death averted ranged from US$10,700 when IFR was 5/1,000 to US$107,700 when IFR was 5/10,000. Deaths averted with the same parameter estimates ranged from 4.7 million to 0.6 million, respectively.

All previously infected scenario
We finally considered a scenario in which Omicron infects 100% of LIC/LMIC population before vaccination is available, and all mortality risk occurs through reinfection. In this instance, the three-dose scenario with natural immunity protection against mortality of 80% and base-case parameters leads to a cost-per-death averted at US$115,000, with 0.5 million deaths averted.

When varying IFR and vaccine effectiveness against mortality, with a cost-per-dose of US$7 cost-per-death averted ranged from US$20,900 with an IFR of 5/1000 and vaccine effectiveness against mortality of 99% and US$230,000 with and IFR of 5/10,000 and vaccine effectiveness against mortality of 90%. Deaths averted with the same parameter estimates ranged from 2.9 million to 0.3 million, respectively.

DISCUSSION
Our analysis suggests that scale-up of vaccination in LIC/LMIC is achievable at justifiable cost, with cost-per-death averted estimates between US$7,400 and US$81,500 for three doses of mRNA vaccine with a US$7 cost per dose. While the estimated cost-per-death averted in LIC/LMIC varies with estimated IFR and vaccine effectiveness against a given COVID-19 variant, all estimates of cost-per-death averted in our analysis are well below the commonly used estimates for the value of a statistical life (VSL), with accepted estimates ranging from €3.7 million in Sweden to $7.3 million in Australia.27–29 Even though cost to avert a death rises at lower COVID-19 IFR, lower vaccine effectiveness, and higher cost per dose, it is a fraction of the US 2022 VSL estimates of US$4.9 million–US$15.9 million.29

Our current analysis focuses on the Omicron variant of COVID-19, a more transmissible but clinically less severe variant than those previously seen. When applying an IFR similar to that seen in previous variants of COVID-19, the number of deaths averted would rise to over 10 million and the cost-per-death averted would drop below US$10,000. If future variants of COVID-19 are more severe than Omicron, the imperative to vaccinate becomes more acute.

Our model does not account for demographic differences among regions, including age structure and the prevalence of comorbid conditions which could affect COVID-19 mortality. Our analysis also did not include limitations on the capacity of health systems, which could affect mortality beyond what we capture with IFR. In addition, we do not attempt to model disease transmission dynamics, or include a temporal component in the model, so we assume anyone without immunity from vaccine or natural protection as of 13 December 2021 retains their risk of COVID-19 mortality through 2022. This is a major limitation given the speed with which the Omicron variant of COVID-19 has been spreading; however, our analysis considering vaccination scale-up after the whole population has been previously infected still estimates a cost-per-death averted of US$115,000. Finally, our main analysis uses reported deaths or excess mortality estimates to estimate rates of prior infection with COVID-19, which are inexact measures especially for the regions of most concern. Nevertheless, they are the best available estimates to date.

Experts have proposed several plans to rapidly expand global COVID-19 vaccine production and delivery.13–17 18 However, the international community has not yet invested the resources required nor displayed the political commitment necessary to scale global vaccination. As a result, 86 countries did not reach the WHO’s target of vaccinating 40% of their populations by the end of 2021.30 This analysis shows that global vaccination can be undertaken for a fraction of the trillions of US$ already spent on global COVID-19 response, and would avert deaths for a cost well below recognised VSL estimates. Whether the investment of USA and other donor nations’ resources for global COVID-19 vaccination are worth spending for this endeavour depends on how we value the lives in LICs and LMICs.

Author affiliations
1Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, Connecticut, USA
2Public Health Modeling Unit, Yale University School of Public Health, New Haven, Connecticut, USA
3Departments of Health Services, Policy, and Practice and Biostatistics, Brown University, Providence, Rhode Island, USA
4Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
5Department of Health Policy and Management, Yale University School of Public Health, New Haven, Connecticut, USA
6Public Citizen, Washington, District of Columbia, USA
7Center for Health Policy/Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, California, USA
8Epidemiology of Microbial Diseases, Yale University Yale School of Public Health, New Haven, Connecticut, USA
9Yale University Yale Law School, New Haven, Connecticut, USA

Correction notice This article has been corrected since it published online to update the funding statement.

Twitter Gregg Gonsalves @gregggonsalves

Contributors GG: guarantor, had the original idea and oversaw analysis and writing. JS: performed main analyses and lead the writing of the manuscript. AB: participated in methods development, idea generating and manuscript editing. MF: participated in methods development, idea generating, and manuscript editing. ADP: participated in costs analysis, idea generating and manuscript editing. ZR: participated in finding data and placing into context, idea generating and manuscript editing. JS: co-led methods development and participated in manuscript editing. TT: participated in idea generation and manuscript editing.
Funding MCF gratefully acknowledges funding from the National Institutes of Health (5K01AI141576). AB and JS were supported by the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT00297-02; AB, JS). Financial support for this study was provided by grants from the National Institute on Drug Abuse DP2 (DA049282 to GSG), R37 (DA15612 to AS, GG, and ADP).

Competing interests None declared.

Patient consent for publication Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. All data used in this study is publicly accessible through the Economist, Our World in Data, Institute for Health Metrics and Evaluation, and the WHO. All code is available at: https://github.com/ASavinkina/COVIDVaccineEquity.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Alexandra Savinkina http://orcid.org/0000-0002-9257-866X
Gergi Gonsalves http://orcid.org/0000-0002-5789-9841

REFERENCES
1. Bank TW. The world by income and region, 2022. Available: https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html [Accessed 17 Jan 2022].
2. Hannah Ritchie EM, Rodés-Guirao L, Appel C. “Coronavirus Pandemic (COVID-19)”. Published online at OurWorldInData.org/ coronavirus, 2020.
3. Irwin A. What it will take to vaccinate the world against COVID-19. Nature 2021;592:176–8.
4. Cohen J, Kupferschmidt K. Fainer shares. Science 2021;372:903–6.
5. Msomi N, Lessells R, Milisana K, et al. Africa: tackle HIV and COVID-19 together. Nature 2021;600:33–6.
6. Mbow M, Leil B, Jochems SP, et al. COVID-19 in Africa: dampening the storm? Science 2020;369:624–6.
7. Schellekens PSD. COVID-19 Mortality in Rich and Poor Countries: A Tale of Two Pandemics? 2020. Available: https://ssrn.com/abstract=3814141
8. Indermit Gill PS. COVID-19 is a developing country pandemic. future development. The Brookings Institution, 2021.
9. Whittaker C, Walker PGT, Alhaffar M, et al. Under-Reporting of deaths limits our understanding of true burden of covid-19. BMJ 2021;375:n2239.
10. Lai H, Khosrawipour V, Kocbach P, et al. Internationally lost COVID-19 cases. J Microbiol Immunol Infect 2020;53:454–8.
11. Economist T. The pandemic’s true death toll–Our daily estimate of excess deaths around the world, 2021. Available: https://github.com/theEconomist/covid-19-excess-deaths-tracker [Accessed 12 Dec 2021].
12. WHO COVID-19 Dashboard. Geneva: World Health organization, 2020. Available: https://covid19.who.int/ [Accessed 07 Jan 2021].
13. Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. Int J Infect Dis 2022;116:38–42.
14. Rössler A, Riepler L, Bante D. SARS-CoV-2 B.1.1.529 variant (omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv 2021;21267491.
15. Zoltan Kis ZR. How to make enough vaccine for the world in one year, 2021. Available: https://www.citizen.org/article/how-to-make-enough-vaccine-for-the-world-in-one-year/
16. Organization WH. Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing, 2021.
17. Ruchir Agarwal GG. A proposal to end the COVID-19. Pandemic: International Monetary Fund, 2021.
18. Citizen P. $25 Billion to Vaccinate the World, 2021. Available: https://www.citizen.org/article/25-billion-to-vaccinate-the-world/
19. Hafner M, Yerushalmi E, Fays C. The global economic cost of COVID-19 vaccine nationalism. Santa Monica, CA: RAND Corporation, 2020.
20. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-Based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant. medRxiv 2021. doi:10.21939/srm.3986405. [Epub ahead of print: 14 Dec 2021].
21. Mathieu E, Ritchie H, Ortiz-Ospina E. A global database of COVID-19 vaccinations. Nat Hum Behav 2021.
22. (IHME) IfHMaE. COVID-19 Mortality, Infection, testing, Hospital resource Use, and Social Distancing Projections. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), University of Washington, 2020.
23. Levin AT, Owusu-Boateng N, Pugh S, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health 2022;7:e008477.
24. Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Mortal Mortal Wkly Rep 2021;70:1539–44.
25. Lewnard JA, Hong VX, Patel MM. Clinical outcomes among patients infected with omicron (B.1.1.529) SARS-CoV-2 variant in southern California. medRxiv 2022;22269045.
26. Colson P, Delerce J, Burel E. Emergence in southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein. medRxiv 2021;21268174.
27. Ananthapavan J, Moodie M, Miliat AJ, et al. Systematic Review to Update ‘Value of a Statistical Life’ Estimates for Australia. Int J Environ Res Public Health 2021;18:6168.
28. Hultkrantz L, Svensson M. The value of a statistical life in Sweden: a review of the empirical literature. Health Policy 2012;108:302–10.
29. Services OOtASfPaEUSDoHaH. Establishing a COVID-19 vaccine technology transfer hub to scale up global manufacturing, 2021.
30. Services UDoHaH, 2016.
31. Colson P, Delerce J, Burel E. Emergence in southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein. medRxiv 2021;21268174.
32. Vasan R, Willet WC, et al. Trends in the “value of a statistical life” in the United States. Am J Epidemiol 2004;159:207–13.
33. Services OOtASfPaEUSDoHaH. Establishing a COVID-19 vaccine technology transfer hub to scale up global manufacturing, 2021.
34. Services UDoHaH, 2016.
35. Colson P, Delerce J, Burel E. Emergence in southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein. medRxiv 2021;21268174.
36. Hafner M, Yerushalmi E, Fays C. The global economic cost of COVID-19 vaccine nationalism. Santa Monica, CA: RAND Corporation, 2020.
37. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-Based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant. medRxiv 2021. doi:10.21939/srm.3986405. [Epub ahead of print: 14 Dec 2021].
38. Mathieu E, Ritchie H, Ortiz-Ospina E. A global database of COVID-19 vaccinations. Nat Hum Behav 2021.
39. (IHME) IfHMaE. COVID-19 Mortality, Infection, testing, Hospital resource Use, and Social Distancing Projections. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), University of Washington, 2020.
40. Levin AT, Owusu-Boateng N, Pugh S, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health 2022;7:e008477.